Anfibatide ( DrugBank: Anfibatide )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 64 | Thrombotic thrombocytopenic purpura | 1 |
64. Thrombotic thrombocytopenic purpura
Clinical trials : 92 / Drugs : 85 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 76
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04021173 (ClinicalTrials.gov) | July 2019 | 15/7/2019 | A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP) | A Multicenter, Randomized, Double-blind, Placebo-parallel, Phase II Clinical Trial of the Efficacy and Safety of Anfibatide in Treating Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP) | Acquired Thrombotic Thrombocytopenic Purpura | Drug: Anfibatide;Drug: Placebos | Lee's Pharmaceutical Limited | NULL | Not yet recruiting | 18 Years | N/A | All | 74 | Phase 2 | China |